Quoin Pharmaceuticals Ltd - AD - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
QNRX Nasdaq 8731 https://quoinpharma.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Quoin Pharmaceuticals Ltd - AD

Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO - Sep 9th, 2024 12:30 pm
QNRX: Assessing QRX003 For Multiple Conditions; Opening International Netherton Syndrome Clinical Sites - Aug 22nd, 2024 11:05 am
Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results - Aug 8th, 2024 12:30 pm
Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome - Aug 6th, 2024 9:00 am
Quoin Pharmaceuticals to Announce Second Quarter 2024 Financial Results on Thursday, August 8, 2024 - Aug 1st, 2024 8:10 pm
Quoin Pharmaceuticals Announces International Expansion of Ongoing Clinical Trials for Netherton Syndrome - Jun 27th, 2024 12:00 pm
Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference - Jun 25th, 2024 8:05 pm
Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland - Jun 12th, 2024 12:00 pm
QNRX: Protocol Modifications Potentially Accelerate, Expand QRX003 Approvals - May 22nd, 2024 2:15 pm
Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results - May 9th, 2024 12:30 pm
Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024 - May 2nd, 2024 8:10 pm
Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q4 2023 Earnings Call Transcript - Mar 15th, 2024 2:52 pm
Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results - Mar 13th, 2024 8:05 pm
Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET - Mar 7th, 2024 9:05 pm
QNRX: Potential Pool of Study Participants Expands; Financial Position Strengths - Mar 5th, 2024 3:12 pm
Quoin Pharmaceuticals Announces Pricing of $6.5 Million Public Offering - Mar 5th, 2024 1:00 pm
Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies - Mar 4th, 2024 1:00 pm
Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination Product - Feb 8th, 2024 1:00 pm
Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome - Dec 13th, 2023 1:30 pm
QNRX: Planned Protocol Modifications Might Accelerate QRX003 Regulatory Approval - Nov 13th, 2023 2:00 pm